FDA approves new labeling for ADHD med

Novartis Pharmaceuticals announced this morning that the FDA has approved new labeling for Focalin XR (dexmethylphenidate HCl), an extended-release stimulant medication aimed at treating attention deficit hyperactivity disorder (ADHD).

The main differentiator for the new labeling is Focalin XR's 30-minute onset, which Novartis reps say will help with early morning struggles, such as getting ready for school.   

The company gained the FDA approval after providing clinical study data showing improvements in attention, deportment and academic productivity in children between the ages of six and 12. The most recent study involved 86 children. 

- read the story at RTT News 

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.